DATA GRAPHICS | Data Byte
Data Byte: GLP-1 sales growing on Ozempic, Trulicity sales
Novo’s Ozempic tops $5B sales in four years
February 4, 2022 12:16 AM UTC
The two leading GLP-1 agonists are growing the class’ share of the diabetes market, with Novo Nordisk’s Ozempic eclipsing $5 billion in sales during its fourth year on the market.
Once-weekly GLP-1 agonist Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) is closing in on market leader Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY). Lilly reported Thursday that Trulicity brought in $6.5 billion in 2021...